尤瑞克林对不同结构性影像类型进展性脑梗死治疗90天的疗效分析

The 90 days follow-up result of mRS after the treatment of kallidinogenase in the patients with progressive cerebral infarction in different imageology styles

目的探讨尤瑞克林对不同结构性影像类型进展性脑梗死治疗90 d的疗效。方法 2007-03～2012-06按入院时不同结构性影像类型将进展性脑梗死分为大灶梗死、中灶梗死、小灶梗死及腔隙梗死4型,共277例,采用分层随机分组的方法将患者分为尤瑞克林组(治疗组)141例,对照组136例。两组基础用药均为疏血通6 ml+生理盐水250 ml静脉滴注;胞磷胆碱0.5 g+生理盐水250 ml静脉滴注;阿司匹林0.1 g口服,以上用药均为1次/d,连用4周。治疗组同时给予生理盐水100 ml+尤瑞克林0.15 PNAu(对硝基苯胺单位)静脉滴注,对照组同时给予生理盐水100 ml静脉滴注,1次/d,连用7～14 d,两组均在疗程结束当天及出院后90 d应用改良Rankin量表(mRS)进行疗效评定。结果治疗后90 d,两组患者mRS评分均继续减少,治疗组中的大、中、小灶梗死组mRS评分减少更为显著,均优于对照组(P<0.05)。结论尤瑞克林能促进进展性脑梗死患者远期神经功能的恢复,降低致残水平。

Objective To investigate the 90 days follow-up result of mRS after the treatment of Urinary kallidinogenase in the patients with progressive cerebral infarction in different imageology styles.Methods Two hundred and seventy-seven patients with progressive cerebral infarction from March 2007 to June 2012 were divided into four subgroups according to different imageology styles：large infarct,middle infarct,small infarct and lacunar infarct.These patients were randomly divided into two groups：treatment group with urinary kallidinogenase（n=141） and control group（n=136）.Two groups were administrated intravenous injection of Shuxuetong 6 ml in physiological saline 250 ml,Citicoline 0.5 g in physiological saline 250 ml and oral aspirin 0.1 g per day for 4 weeks.On the basis of above treatment,treatment group was administrated intravenous infusion of urinary kallidinogenase 0.15 PNAu in physiological saline 100 ml,control group was administrated physiological saline 100 ml per day for 7~14 days.The efficacy was evaluated by mRS（Modified Rankin Scale） at the end of treatment and 90 days after-discharge respectively.Results The resuts showed that 90 days affter-discharge,the scores of mRS in two groups decreased,especially in large infarct,middle infarct and small infarct subgroups.The treatment group was superior to control group in decrease of the scores of mRs（P＆lt;0.05）.Conclusion Urinary kallidinogenase is effective to promote long-term neurofunctional recovery and step down mutilation of progressive cerebral infarction.